Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anxiety and related disorders include generalised anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and phobic disorders (intense fear of an object or situation). These disorders share the psychological and physical symptoms of anxiety, but each disorder has its own set of characteristic symptoms. Anxiety disorders can be difficult to recognise, particularly in older people (those aged over 65 years). Older people tend to be more reluctant to discuss mental health issues and there is the perception that older people are generally more worried than younger adults. It is estimated that between 3 and 14 out of every 100 older people have an anxiety disorder. Despite treatment, some people will continue to have symptoms of anxiety. People are generally considered to be 'resistant' or 'refractory' to treatment if they have an inadequate response or do not respond to their first treatment. Older adults with an anxiety disorder find it difficult to manage their day-to-day lives and are at an increased risk of comorbid depression, falls, physical and functional disability, and loneliness. OBJECTIVE: To evaluate the effectiveness of pharmacological, psychological and alternative therapies in older adults with an anxiety disorder who have not responded, or have responded inadequately, to treatment. DATA SOURCES: Electronic databases (MEDLINE, MEDLINE In-Process and Other Non-Indexed citations, EMBASE, The Cochrane Library databases, PsycINFO and Web of Science) were searched from inception to September 2013. Bibliographies of relevant systematic reviews were hand-searched to identify additional potentially relevant studies. ClinicalTrials.gov was searched for ongoing and planned studies. REVIEW METHODS: A systematic review of the clinical effectiveness of treatments for treatment-resistant anxiety in older adults was carried out. RESULTS: No randomised controlled trial or prospective comparative observational study was identified meeting the prespecified inclusion criteria. Therefore, it was not possible to draw any conclusions on clinical effectiveness. LIMITATIONS: As no study was identified in older adults, there is uncertainty as to which treatments are clinically effective for older adults with an anxiety disorder who have not responded to prior treatment. The comprehensive methods implemented to carry out this review are a key strength of the research presented. However, this review highlights the extreme lack of research in this area, identifying no comparative studies, which is a marked limitation. CONCLUSIONS: Specific studies evaluating interventions in older adults with an anxiety disorder who have not responded to first-line treatment are needed to address the lack of evidence. The lack of evidence in this area means that older adults are perhaps receiving inappropriate treatment or are not receiving a particular treatment because there is limited evidence to support its use. At this time there is scope to develop guidance on service provision and, as a consequence, to advance the standard of care received by older adults with a treatment-resistant anxiety disorder in primary and secondary care. Evaluation of the relative clinical effectiveness and acceptability of pharmacological and psychological treatment in older adults with an anxiety disorder that has not responded to first-line treatment is key future research to inform decision-making of clinicians and patients. An important consideration would be the enrolment of older adults who would be representative of older adults in general, i.e. those with multiple comorbid physical and mental disorders who might require polypharmacy. STUDY REGISTRATION: The protocol for the systematic review is registered on PROSPERO (registration number CRD42013005612). FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As noted in Chapter 1, guidance on managing TR-GAD in older people (and indeed in working-age people) is lacking.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A previous systematic review 35 was unable to identify any randomised controlled trial (RCT) or prospective comparative study of either pharmacological or psychological interventions for treatment-resistant anxiety in older people.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“A previous systematic review 35 was unable to identify any randomised controlled trial (RCT) or prospective comparative study of either pharmacological or psychological interventions for treatment-resistant anxiety in older people.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“For example, a previous systematic review was unable to identify any randomised controlled trial (RCT) or prospective comparative observational study of pharmacotherapy or psychotherapy for treatment-resistant anxiety in older people [8].”
From Acceptance and commitment therapy for late-life treatment-resistant generalised anxiety disorder: a feasibility study. (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“A US-based study (9282 English-speaking respondents aged ≥ 18 years) reported the median age at onset of anxiety disorders to be 11 years.(2) Although anxiety disorders among older people (≥ 65 years) are less common than in younger adults, it is acknowledged that the frequency in older adults is considerably higher t…”
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318 · cited 3×
“When a threat is perceived, various neurotransmitters and other chemical messengers, including circulating hormones, are released to modulate the neural circuitry involved in the generation of feelings of fear and anxiety.(22) The chief hormone involved in the autonomic nervous system is the catecholamine ‘adrenaline’…”
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009 · cited 1×
“Dysregulation of the hypothalamo–pituitary–adrenal axis is known to be associated with an increased risk of development of major depression.(24) Furthermore, the ageing brain is less able to downregulate the hypothalamo–pituitary–adrenal axis and is more susceptible to physiological stressors.”
Julian, L. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20561 · Cited by 1,794 · cited 2×
“By contrast, the Hospital Anxiety and Depression Scale evaluates the presence of symptoms of anxiety and depression in physically ill people.(18) The effects of variation in language, education and culture across ethnic groups can lead to variation in judging the severity of patients’ symptoms.”
Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2002) · Nature Neuroscience · doi:10.1038/nn958 · Cited by 1,635 · cited 1×
“However, recent research involving identical (monozygotic) twins suggests that reduced hippocampal volume is predetermined and volume is linked with susceptibility to PTSD.(33) Other studies in identical or non-identical (dizygotic) twins have found that all the anxiety disorders have a moderately strong genetic basis…”
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.7.973 · Cited by 1,610
A Review and Meta-Analysis of the Genetic Epidemiology of Anxiety Disorders
Hettema, J. M., Neale, M. C., & Kendler, K. S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1568 · Cited by 1,563 · cited 1×
“Other studies in identical or non-identical (dizygotic) twins have found that all the anxiety disorders have a moderately strong genetic basis, accounting for 30–40% of the probability of a person developing an anxiety disorder.(34,35)”
Research works printed but not linked: 20
- American Psychiatric Association, 2013, Highlights of Changes from DSM-IV-TR to DSM-5
- Gellis, 2007, Anxiety Disorders among Older Adults (literature review)
- National Collaborating Centre for Mental Health, 2011, Generalised Anxiety Disorder in Adults. The NICE Guideline on Management In Primary, Secondary and Community Care
- National Collaborating Centre for Mental Health, 2005, Post-Traumatic Stress Disorder. The Management of PTSD in Adults and Children in Primary and Secondary Care
- National Collaborating Centre for Mental Health, 2005, Obsessive–Compulsive Disorder: Core Interventions in the Treatment of Obsessive–Compulsive Disorder and Body Dysmorphic Disorder
- National Collaborating Centre for Mental Health, 2013, Social Anxiety Disorder: Recognition, Assessment and Treatment
- National Institute for Health and Care Excellence, 2013, Pathway for Generalised Anxiety Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Panic Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Obsessive–Compulsive Disorder and Body Dysmorphic Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Post-Traumatic Stress Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Social Anxiety Disorder
- Gale C, Millichamp J. Generalised Anxiety Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence.bmj.com/x/systematic-review/1002/interventions.html (accessed December 2013).
- Kumar S, Malone D. Panic Disorder. Clinical Evidence, 2008. URL: http://clinicalevidence.bmj.com/x/systematic-review/1010/interventions.html (accessed December 2013).
- Bisson JI. Post-Traumatic Stress Disorder. Clinical Evidence, 2009. URL: http://clinicalevidence.bmj.com/x/systematic-review/1005/interventions.html (accessed December 2013).
- Soomro GM. Obsessive Compulsive Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence.bmj.com/x/systematic-review/1004/interventions.html (accessed December 2013).
- Centre for Reviews and Dissemination, 2013, Clinical Effectiveness of Interventions for Treatment-Resistant Anxiety in Older People: a Systematic Review (PROSPERO record)
- Scottish Intercollegiate Guidelines Network, 2013, Search Filters
- Clinical Evidence. Study Design Search Filters. 2013. URL: http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html (accessed December 2013).
- Ginsberg, 2005, Ziprasidone for treatment-resistant generalized anxiety disorder, Prim Psychiatry, 12, 28
- Prasko, 2007, The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study, Neuro Endocrinol Lett, 28, 33
Cited by
Stress, glucocorticoids and memory: implications for treating fear-related disorders
de Quervain, D., Schwabe, L., & Roozendaal, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.155 · Cited by 484
Glucocorticoid-induced enhancement of extinction—from animal models to clinical trials
de Quervain, D. J. ‐., Wolf, O. T., & Roozendaal, B. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5116-0 · Cited by 89
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“The varying terminology reflects the absence of consensus regarding the criteria for TR (Barton et al., 2014; Cirillo, Freire, & Freire, 2016; Perna & Caldirola, 2017; Stein & Seedat, 2004; Yoshinaga et al., 2016).”
BackgroundInfluentialDomschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
Self-citationClinical characteristics of generalized anxiety disorder: older vs. young adults
Altunöz, U., Kokurcan, A., Kirici, S., Baştuğ, G., & Ozel-Kizil, E. T. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1390607 · Cited by 38
“However, diagnosis and management of GAD in the older adults remain as a dilemma in clinical practice [9].”
BackgroundGould, R. L., Wetherell, J. L., Kimona, K., Serfaty, M. A., Jones, R., Graham, C. D., Lawrence, V., Livingston, G., Wilkinson, P., Walters, K., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab059 · Cited by 33
“For example, a previous systematic review was unable to identify any randomised controlled trial (RCT) or prospective comparative observational study of pharmacotherapy or psychotherapy for treatment-resistant anxiety in older people [8].”
BackgroundA multispecies probiotic accelerates fear extinction and inhibits relapse in mice: Role of microglia
Cui, X., Zhou, S., Xia, G., Chen, J., Jiang, L., Huang, J., & Tong, J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108613 · Cited by 26
Lawrence, V., Kimona, K., Howard, R. J., Serfaty, M. A., Wetherell, J. L., Livingston, G., Wilkinson, P., Walters, K., Jones, R., Wuthrich, V. M., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz082 · Cited by 19
“The older adult population is projected to increase rapidly in the next 40 years [6], yet there is a stark lack of evidence to guide the management of older adults with ‘treatment-resistant’ GAD whose symptoms persist beyond first-line treatment [7].”
BackgroundFond, G. B., Fajula, C., Dassa, D., Brunel, L., Lançon, C., & Boyer, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4312-z · Cited by 19
“To date, no intervention for treatment-resistant anxiety in the elderly inpatients has proven its efficacy (Barton et al. 2014).”
BackgroundObsessive-Compulsive Disorder in Older Adults: A Comprehensive Literature Review
Jazi, A. N., & Asghar‐Ali, A. A. (2020) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000463 · Cited by 21
Hofmann, V. (2023) · Frontiers in Education · doi:10.3389/feduc.2023.1157248 · Cited by 26
“First, people affected by severe anxiety often experience diverse symptoms of emotional and physical discomfort (Hoffman et al., 2008; Barton et al., 2014).”
BackgroundOff-label use of antipsychotics and associated factors in community living older adults
Bakouni, H., Berbiche, D., & Vasiliadis, H. (2017) · Aging & Mental Health · doi:10.1080/13607863.2017.1401583 · Cited by 12
Hu, X., Ma, Y., Karako, K., Tang, W., Song, P., & Xia, Y. (2024) · BioScience Trends · doi:10.5582/bst.2024.01100 · Cited by 16
Stojanović, N. M., Randjelović, P. J., Nikolić, G., Stojiljković, N. I., Ilić, S., Stoiljković, B., & Radulović, N. S. (2019) · AFMN Biomedicine · doi:10.5937/afmnai37-25011 · Cited by 16
“Acta facultatis medicae Naissensis 2020; 37(2):149-159 154 Figure 2.”
InfluentialEiset, A. H., Loua, A. S., Kruse, A., & Nørredam, M. L. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01501-4 · Cited by 10
Jerjes, W., & Harding, D. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1384835 · Cited by 7
Hatch, S., Finlayson, M. L., Rej, S., & Kessler, D. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.04.007 · Cited by 5
Gould, R. L., Wetherell, J. L., Serfaty, M. A., Kimona, K., Lawrence, V., Jones, R., Livingston, G., Wilkinson, P., Walters, K., Novere, M. L., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25540 · Cited by 4
Schiele, M. A., Fagan, H. A., Baldwin, D. S., & Domschke, K. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000547926 · Cited by 7
“…age patients, often complicated by multiple comorbid physical and mental disorders as well as polypharmacy, has not been studied specifically so far and should be subject to investigation in order to establish a safe and effective standard of care received by older adults with TR-AD [138, 139].”
Self-citationChildhood abuse/neglect and temporal patterns in late-life anxiety
Bakouni, H., Ouimet, M. C., Desjardins, S., Forget, H., & Vasiliadis, H. (2022) · Aging & Mental Health · doi:10.1080/13607863.2022.2076204 · Cited by 5
Nature and reporting characteristics of UK health technology assessment systematic reviews
Carroll, C., & Kaltenthaler, E. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0498-6 · Cited by 4
“It is clear, however, that every effort was made in these reviews to find useable evidence from any comparative study design, but the only available data were from trials with completely different groups in each arm [13] or the complete absence of any relevant comparative studies at all, of any design [14].”
BackgroundSzlyk, H. S., Dell, N. A., Li, X., Winograd, R., & Cavazos‐Rehg, P. A. (2025) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2025.2471330 · Cited by 5
“The General Anxiety Disorder-7 (GAD-7) is a valid and efficient screening tool assessing the severity of anxiety symptoms in clinical practice and research, based on selected criteria from the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5) for GAD (Barton et al., 2014; Spitzer et al., 20…”
InfluentialKaeley, N., Dhar, M., Bhat, N. K., Ahmad, S., & Rawat, A. (2018) · Journal of Clinical and Preventive Cardiology · doi:10.4103/jcpc.jcpc_14_18 · Cited by 2
Sauroxine reduces memory retention in rats and impairs hippocampal long-term potentiation generation
Vallejo, M. G., Carlini, V. P., Gabach, L. A., Ortega, M. G., Cabrera, J. L., de Barioglio, S. R., Pérez, M. F., & Agnese, A. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.016 · Cited by 2
“Nevertheless, symptomatology of PTSD persists despites the current medications received by the patients [30].”
Carlier, I. V. E., van der Elst, L. V., de Jong, K., & van Vliet, I. M. (2023) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001667 · Cited by 2
Ortiz-Juza, M. M., Ung, R. L., Hegel, S. M., Ring, A. L., Miller, N. W., Garcia-Reyes, R. A., Nomura, H., Kato, H., Pégard, N. C., & Rodríguez-Romaguera, J. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100538 · Cited by 1
Current Clinical Trials to Treat Anxiety Disorders in the Elderly: A Registry-Based Review
Dietz, G. P. H., & Riepe, M. W. (2026) · Pharmaceuticals · doi:10.3390/ph19060891 · Cited by 1
Papel da memantina no tratamento das perturbações da ansiedade: uma revisão baseada na evidência
Marques, A. R. M., & de Marins, N. D. (2016) · Jornal Brasileiro de Psiquiatria · doi:10.1590/0047-2085000000121
“Da pesquisa, resultou ainda uma revisão sistemática de Barton et al.14, de 2014, com o objetivo de avaliar a eficácia do tratamento farmacológico e psicológico e terapias alternativas em idosos com perturbações de ansiedade.”
BackgroundPharmacological Management of Anxiety and Depression in Older People
Wilkinson, P., & Behrman, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-29492-6_9
Costa, R. L., de Oliveira, M. F., de Oliveira, P. F., França, M. A. A., dos Santos, M. D. S., Falcão, M. F., & Menezes, C. J. J. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592342206074
Castañeda, D. P. M., & Torres, L. I. N. (2022) · International Journal of Health Science · doi:10.22533/at.ed.1592422229077
Al-Khathami, A. D. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002421
Primary Care Medicine - Theory and Practice
Çakmur, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111122 · Cited by 1
Effectiveness of Art Therapy in Reducing State Anxiety among Persons with Intellectual Disabilities
-, T. M., -, S. D., & -, S. S. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i02.15107
Gould, R. L., Callaghan, T., White, D., Wetherell, J. L., Bursnall, M., Bradburn, M., Wailoo, A., Serfaty, M. A., Graham, C. D., Howard, R. J., et al. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07094-6
Metadata
- Authors
- Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J.
- Affiliations
- BMJ Group (United Kingdom) (GB)
- University of Southampton (GB)
- Corresponding author
- Barton, Samantha
- Venue
- Health Technology Assessment
- Published
- 2014-08
- Volume
- 18
- Issue
- 50
- Pages
- 1-60
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC4781619
- OpenAlex
- W2081899968
- Cited by
- 36
- References
- 175
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 4
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute for Health Research (13/39/01)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- treatment-resistant anxiety, older adults, anxiety disorders, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, phobia, pharmacotherapy, psychological intervention, complementary and alternative medicine, comorbid depression, falls, functional disability, loneliness, absence of evidence, research gaps, treatment non-response
- MeSH terms
- Age Factors, Aged, Anxiety, Humans, Psychotherapy, Anti-Anxiety Agents, Treatment Outcome, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.